Weston, Massachusetts
United States
39
2024-10-17
The entities that hold a legal rights for patent applications filed by inventor Bradner James:
James Bradner from Weston, US has applied for patents for these inventions. The list has both pending applications and granted patents:
CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES
#2 | 2024-09-19DEGRADATION OF EXTRACELLULAR TARGETS
#3 | 2024-03-21COMPOUNDS AND METHODS FOR TREATING CANCER
#4 | 2023-09-07COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
#5 | 2023-04-27DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
#6 | 2022-05-05TUNABLE ENDOGENOUS PROTEIN DEGRADATION
#7 | 2022-01-13Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies
#8 | 2021-09-30TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES
#9 | 2021-05-20Compounds and methods for treating cancer
#10 | 2021-03-04Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
#11 | 2021-01-21Methods to induce targeted protein degradation through bifunctional molecules
#12 | 2020-10-08Methods to induce targeted protein degradation through bifunctional molecules
#13 | 2020-07-09BIFUNCTIONAL MOLECULES FOR HER3 DEGRADATION AND METHODS OF USE
#14 | 2020-01-23Chromobox protein inhibitors and uses thereof
#15 | 2020-01-09Compounds and methods for treating cancer
#16 | 2019-12-12Tunable endogenous protein degradation with heterobifunctional compounds
#17 | 2019-12-12Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
#18 | 2019-12-05Regulating chimeric antigen receptors
#19 | 2019-10-17Calmodulin inhibitors, Chk2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies
#20 | 2019-08-29Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
#21 | 2019-08-15Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
#22 | 2019-07-11Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of use
#23 | 2019-05-23Methods to induce targeted protein degradation through bifunctional molecules
#24 | 2019-05-09METHODS OF DOWNREGULATING TRANSLOCATED ONCOGENE EXPRESSION USING BROMODOMAIN INHIBITORS
#25 | 2019-03-07Methods to induce targeted protein degradation through bifunctional molecules
#26 | 2019-01-17BIFUNCTIONAL COMPOUNDS FOR HER3 DEGRADATION AND METHODS OF USE
#27 | 2018-11-15Targeted protein degradation using a mutant E3 ubiquitin ligase
#28 | 2018-06-28Tunable endogenous protein degradation
#29 | 2018-06-21Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses
#30 | 2018-05-31Compounds and methods for treating cancer
#31 | 2018-05-17Methods to induce targeted protein degradation through bifunctional molecules
#32 | 2018-03-29METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES
#33 | 2018-01-11Methods to induce targeted protein degradation through bifunctional molecules
#34 | 2017-12-21Bromodomain inhibitor as adjuvant in cancer immunotherapy
#35 | 2016-08-25Methods to induce targeted protein degradation through bifunctional molecules
#36 | 2016-08-18Methods to induce targeted protein degradation through bifunctional molecules
#37 | 2016-08-18Methods to induce targeted protein degradation through bifunctional molecules
#38 | 2016-06-23Methods to induce targeted protein degradation through bifunctional molecules
#39 | 2014-12-18Method for identifying bromodomain inhibitors
1007420 ⎘